The discovery of androgen dependence in prostate cancer in 1941 by Huggins and
colleagues has remained the backbone for the treatment of this disease. However, although …

Owing to the development of multiple novel therapies, there has been major progress in the
treatment of advanced prostate cancer over the last two decades; however, the disease …

Purpose Antiandrogens inhibit the androgen receptor and have an important role in the
treatment of prostate cancer. This review provides a historical perspective on the …

Since the year 2000, tremendous progress has been made in the understanding of
castration-resistant prostate cancer (CRPC), a disease state now recognized to retain …

The androgen receptor is a transcription factor and validated therapeutic target for prostate
cancer. Androgen deprivation therapy remains the gold standard treatment, but it is not …

Androgens play an essential role in prostate cancer. Clinical treatments that target
steroidogenesis and the androgen receptor (AR) successfully postpone disease …

What's known on the subject? and What does the study add? Castration resistance has
been appreciated for decades, and several mechanisms theorising on this effect have been …

Persistent androgen receptor (AR) signaling despite low levels of serum androgens has
been identified as a critical target for drug discovery in castration-resistant prostate cancer …

Castration-resistant prostate cancer (CRPC), the invariably lethal phenotype of advanced
prostate cancer, represents a clinical state defined by disease progression despite reduction …

Prostate cancer is the most commonly diagnosed cancer affecting men in the United States.
The prostate is a hormone-dependent gland in which androgen hormones testosterone and …